A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir

BackgroundNew multi-purpose prevention technology (MPT) products are needed to prevent human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV2). In this study, we evaluated a fast-dissolve insert that may be used vaginally or rectally for prevention of infection.ObjectiveTo describe...

Full description

Bibliographic Details
Main Authors: Andrea R. Thurman, Louise A. Ouattara, Nazita Yousefieh, Peter L. Anderson, Lane R. Bushman, Xi Fang, Homaira Hanif, Meredith Clark, Onkar Singh, Gustavo F. Doncel
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
vaginal insert
tenofovir alafenamide
elvitegravir
microbicide agent
HIV prevention
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2023.1130101/full

Internet

https://www.frontiersin.org/articles/10.3389/fcimb.2023.1130101/full

Similar Items